Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Melanie Senior

Contributor

London, UK

Experienced biopharmaceutical industry analyst, reporter & commentator following strategic, commercial and scientific issues affecting the sector. Regular contributor to Nature Biotechnology, Informa Business Intelligence (IN VIVO, Datamonitor, Scrip) and EY Life Sciences. Specialist & feature coverage and consulting across market access, pricing, outcomes-based care, precision medicine, digital health, AI, R&D strategies and consumer empowerment for a range of clients in biopharma and investment community.

Latest From Melanie Senior

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals

On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster

Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.

Respiratory Clinical Trials

Re-Thinking Rare Disease

Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.

Cost Effectiveness Rare Diseases

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Business Strategies Financing

The IPO Party Is Over – How Bad Is The Hangover?

Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?

Financing Market Intelligence

The Other Pandemic

When Novo Nordisk’s anti-obesity medicine Wegovy launched in June 2021, patients and physicians could not get enough. As COVID-19 underscored the risks of obesity, along came the most effective drug yet – on a par with surgery, in terms of weight loss achieved. Pharma’s interest in this disease has reawakened, and Wegovy may be just the first of a new generation of more powerful anti-obesity medicines.

Innovation Strategy
See All
UsernamePublicRestriction

Register